Precision Medicine

Cornucopian Capital Brings Precision Health to the Masses
Tech & Innovation Cornucopian Capital Brings Precision Health to the Masses

Advances in protein design and enzyme engineering now allow for the rapid modification of bioactive substances, such as decaffeinating beverages in minutes by mimicking the body’s natural metabolic pathways. This breakthrough represents a broader shift toward what Aryeh Ganz and Cornucopian Capital

Can Off-the-Shelf CAR T Therapy Prevent Lymphoma Relapse?
Research & Development Can Off-the-Shelf CAR T Therapy Prevent Lymphoma Relapse?

Detecting minimal residual disease through high-sensitivity blood tests allows clinicians to identify high-risk patients who might benefit from immediate cellular therapy despite appearing to be in remission. This shift toward early intervention represents a departure from traditional

Can DNA Predict Blood Cancer Years Before Symptoms?
Research & Development Can DNA Predict Blood Cancer Years Before Symptoms?

The discovery of genetic precursors to myelofibrosis offers a critical window of opportunity for clinicians to shift from reactive treatment models toward proactive, personalized surveillance strategies. For decades, the medical community has struggled with the silent progression of

Can AI Predict Cancer Mutations From Standard Tissue Slides?
Tech & Innovation Can AI Predict Cancer Mutations From Standard Tissue Slides?

By identifying relevant microscopic patterns across large image patches, new AI models can process the immense complexity of whole slide images much faster than manual human observation. Modern computational pathology is undergoing a radical transformation as deep learning architectures move beyond

Institutional Capital Shifts to Precision Medicine
Management & Regulatory Institutional Capital Shifts to Precision Medicine

The global healthcare landscape is undergoing a monumental transition as the traditional "one-size-fits-all" model gives way to a more sophisticated, precision-based framework. This evolution represents both a significant scientific leap and a massive economic shift that is reshaping how global

Is the 82-Fold ROI of AI in Clinical Trials a Site Burden?
Research & Development Is the 82-Fold ROI of AI in Clinical Trials a Site Burden?

The clinical research industry is currently weathering a transformative storm where the sheer velocity of data collection frequently outpaces the logistical capacity of the human teams working on the front lines of patient care. While high-level financial metrics suggest an unprecedented era of

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later